PET/CT and biochemical recurrence of prostate adenocarcinoma: Added value of 68 Ga-PSMA-11 when 18 F-fluorocholine is non-contributive
Since April 201, we have introduced PET/CT using a ligand of prostate-specific membrane antigen labeled with gallium-68 (PSMA-11). We aimed to evaluate its positivity rate and impact in patients presenting biochemical recurrence of prostate cancer whose F-fluorocholine (FCH) PET/CT was non-contribut...
Gespeichert in:
| Veröffentlicht in: | Progrès en urologie (Paris) 2017-06, Vol.27 (8-9), p.474 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | fre |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 8-9 |
| container_start_page | 474 |
| container_title | Progrès en urologie (Paris) |
| container_volume | 27 |
| creator | Gauthé, M Belissant, O Girard, A Zhang Yin, J Ohnona, J Cottereau, A-S Nataf, V Balogova, S Pontvert, D Lebret, T Guillonneau, B Cussenot, O Talbot, J-N |
| description | Since April 201, we have introduced PET/CT using a ligand of prostate-specific membrane antigen labeled with gallium-68 (PSMA-11). We aimed to evaluate its positivity rate and impact in patients presenting biochemical recurrence of prostate cancer whose
F-fluorocholine (FCH) PET/CT was non-contributive.
Patients were prospectively included between April and December 2016. PET/CT was performed 60min after injection of 2MBq/kg of body mass of
Ga-PSMA-11. Three anatomical areas were considered: prostatic lodge, pelvic lymph nodes and distant locations. The impact of PSMA-11 PET/CT was assessed by comparing changes in therapeutic strategy decided during multidisciplinary meeting.
Thirty-three patients were included. The mean PSA serum level measured on the month of the PSMA-11 PET/CT was 2,8ng/mL. Twenty-five (76%) PSMA-11 PET/CT were positive, 7 (21%) negative and 1 (3%) equivocal. Of 11 patients whose FCH PET/CT showed equivocal foci, PSMA-11 PET/CT confirmed those foci in 5 cases. Follow-up was available for 18 patients (55%). PSMA-11 PET/CT results led to a change in management in 12 patients (67%).
Ga-PSMA-11 PET/CT is useful in detecting recurrence of prostate cancer, by identifying residual disease which was not detected on other imaging modalities and by changing management of 2 patients out of 3.
5. |
| doi_str_mv | 10.1016/j.purol.2017.04.004 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_28576423</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>28576423</sourcerecordid><originalsourceid>FETCH-pubmed_primary_285764233</originalsourceid><addsrcrecordid>eNqFjktOwzAUAL0A0fI5ARJ6F3D6nAbHsKuqtmyQKpF95dgvqivHjpy4iAtwbhCCNavZjEbD2L3AQqCQi1Mx5BR9UaKoC6wKxOqCzYWQkteo6hm7HscTokRUT1dsVqrHWlblcs4-95tmsW5ABwuti-ZIvTPaQyKTU6JgCGIHQ4rjpCcCbSlEo5NxIfb6GVbWkoWz9vnHkwp2mu_fXldcCHg_UgChYMs7n2P6jkfvAoEbIcTATQxTcm2e3Jlu2WWn_Uh3v7xhD9tNs37hQ257sochuV6nj8Pf-PJf4QuMWFR-</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>PET/CT and biochemical recurrence of prostate adenocarcinoma: Added value of 68 Ga-PSMA-11 when 18 F-fluorocholine is non-contributive</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Gauthé, M ; Belissant, O ; Girard, A ; Zhang Yin, J ; Ohnona, J ; Cottereau, A-S ; Nataf, V ; Balogova, S ; Pontvert, D ; Lebret, T ; Guillonneau, B ; Cussenot, O ; Talbot, J-N</creator><creatorcontrib>Gauthé, M ; Belissant, O ; Girard, A ; Zhang Yin, J ; Ohnona, J ; Cottereau, A-S ; Nataf, V ; Balogova, S ; Pontvert, D ; Lebret, T ; Guillonneau, B ; Cussenot, O ; Talbot, J-N</creatorcontrib><description>Since April 201, we have introduced PET/CT using a ligand of prostate-specific membrane antigen labeled with gallium-68 (PSMA-11). We aimed to evaluate its positivity rate and impact in patients presenting biochemical recurrence of prostate cancer whose
F-fluorocholine (FCH) PET/CT was non-contributive.
Patients were prospectively included between April and December 2016. PET/CT was performed 60min after injection of 2MBq/kg of body mass of
Ga-PSMA-11. Three anatomical areas were considered: prostatic lodge, pelvic lymph nodes and distant locations. The impact of PSMA-11 PET/CT was assessed by comparing changes in therapeutic strategy decided during multidisciplinary meeting.
Thirty-three patients were included. The mean PSA serum level measured on the month of the PSMA-11 PET/CT was 2,8ng/mL. Twenty-five (76%) PSMA-11 PET/CT were positive, 7 (21%) negative and 1 (3%) equivocal. Of 11 patients whose FCH PET/CT showed equivocal foci, PSMA-11 PET/CT confirmed those foci in 5 cases. Follow-up was available for 18 patients (55%). PSMA-11 PET/CT results led to a change in management in 12 patients (67%).
Ga-PSMA-11 PET/CT is useful in detecting recurrence of prostate cancer, by identifying residual disease which was not detected on other imaging modalities and by changing management of 2 patients out of 3.
5.</description><identifier>ISSN: 1166-7087</identifier><identifier>DOI: 10.1016/j.purol.2017.04.004</identifier><identifier>PMID: 28576423</identifier><language>fre</language><publisher>France</publisher><subject>Adenocarcinoma - blood ; Adenocarcinoma - diagnostic imaging ; Adenocarcinoma - surgery ; Aged ; Biomarkers - blood ; Choline - analogs & derivatives ; Follow-Up Studies ; Gallium Radioisotopes ; Humans ; Male ; Middle Aged ; Neoplasm Recurrence, Local - blood supply ; Neoplasm Recurrence, Local - diagnostic imaging ; Neoplasm Recurrence, Local - surgery ; Positron Emission Tomography Computed Tomography - methods ; Prospective Studies ; Prostate-Specific Antigen - blood ; Prostatectomy ; Prostatic Neoplasms - blood ; Prostatic Neoplasms - diagnostic imaging ; Prostatic Neoplasms - surgery ; Radiopharmaceuticals ; Treatment Outcome</subject><ispartof>Progrès en urologie (Paris), 2017-06, Vol.27 (8-9), p.474</ispartof><rights>Copyright © 2017 Elsevier Masson SAS. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28576423$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gauthé, M</creatorcontrib><creatorcontrib>Belissant, O</creatorcontrib><creatorcontrib>Girard, A</creatorcontrib><creatorcontrib>Zhang Yin, J</creatorcontrib><creatorcontrib>Ohnona, J</creatorcontrib><creatorcontrib>Cottereau, A-S</creatorcontrib><creatorcontrib>Nataf, V</creatorcontrib><creatorcontrib>Balogova, S</creatorcontrib><creatorcontrib>Pontvert, D</creatorcontrib><creatorcontrib>Lebret, T</creatorcontrib><creatorcontrib>Guillonneau, B</creatorcontrib><creatorcontrib>Cussenot, O</creatorcontrib><creatorcontrib>Talbot, J-N</creatorcontrib><title>PET/CT and biochemical recurrence of prostate adenocarcinoma: Added value of 68 Ga-PSMA-11 when 18 F-fluorocholine is non-contributive</title><title>Progrès en urologie (Paris)</title><addtitle>Prog Urol</addtitle><description>Since April 201, we have introduced PET/CT using a ligand of prostate-specific membrane antigen labeled with gallium-68 (PSMA-11). We aimed to evaluate its positivity rate and impact in patients presenting biochemical recurrence of prostate cancer whose
F-fluorocholine (FCH) PET/CT was non-contributive.
Patients were prospectively included between April and December 2016. PET/CT was performed 60min after injection of 2MBq/kg of body mass of
Ga-PSMA-11. Three anatomical areas were considered: prostatic lodge, pelvic lymph nodes and distant locations. The impact of PSMA-11 PET/CT was assessed by comparing changes in therapeutic strategy decided during multidisciplinary meeting.
Thirty-three patients were included. The mean PSA serum level measured on the month of the PSMA-11 PET/CT was 2,8ng/mL. Twenty-five (76%) PSMA-11 PET/CT were positive, 7 (21%) negative and 1 (3%) equivocal. Of 11 patients whose FCH PET/CT showed equivocal foci, PSMA-11 PET/CT confirmed those foci in 5 cases. Follow-up was available for 18 patients (55%). PSMA-11 PET/CT results led to a change in management in 12 patients (67%).
Ga-PSMA-11 PET/CT is useful in detecting recurrence of prostate cancer, by identifying residual disease which was not detected on other imaging modalities and by changing management of 2 patients out of 3.
5.</description><subject>Adenocarcinoma - blood</subject><subject>Adenocarcinoma - diagnostic imaging</subject><subject>Adenocarcinoma - surgery</subject><subject>Aged</subject><subject>Biomarkers - blood</subject><subject>Choline - analogs & derivatives</subject><subject>Follow-Up Studies</subject><subject>Gallium Radioisotopes</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - blood supply</subject><subject>Neoplasm Recurrence, Local - diagnostic imaging</subject><subject>Neoplasm Recurrence, Local - surgery</subject><subject>Positron Emission Tomography Computed Tomography - methods</subject><subject>Prospective Studies</subject><subject>Prostate-Specific Antigen - blood</subject><subject>Prostatectomy</subject><subject>Prostatic Neoplasms - blood</subject><subject>Prostatic Neoplasms - diagnostic imaging</subject><subject>Prostatic Neoplasms - surgery</subject><subject>Radiopharmaceuticals</subject><subject>Treatment Outcome</subject><issn>1166-7087</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFjktOwzAUAL0A0fI5ARJ6F3D6nAbHsKuqtmyQKpF95dgvqivHjpy4iAtwbhCCNavZjEbD2L3AQqCQi1Mx5BR9UaKoC6wKxOqCzYWQkteo6hm7HscTokRUT1dsVqrHWlblcs4-95tmsW5ABwuti-ZIvTPaQyKTU6JgCGIHQ4rjpCcCbSlEo5NxIfb6GVbWkoWz9vnHkwp2mu_fXldcCHg_UgChYMs7n2P6jkfvAoEbIcTATQxTcm2e3Jlu2WWn_Uh3v7xhD9tNs37hQ257sochuV6nj8Pf-PJf4QuMWFR-</recordid><startdate>201706</startdate><enddate>201706</enddate><creator>Gauthé, M</creator><creator>Belissant, O</creator><creator>Girard, A</creator><creator>Zhang Yin, J</creator><creator>Ohnona, J</creator><creator>Cottereau, A-S</creator><creator>Nataf, V</creator><creator>Balogova, S</creator><creator>Pontvert, D</creator><creator>Lebret, T</creator><creator>Guillonneau, B</creator><creator>Cussenot, O</creator><creator>Talbot, J-N</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>201706</creationdate><title>PET/CT and biochemical recurrence of prostate adenocarcinoma: Added value of 68 Ga-PSMA-11 when 18 F-fluorocholine is non-contributive</title><author>Gauthé, M ; Belissant, O ; Girard, A ; Zhang Yin, J ; Ohnona, J ; Cottereau, A-S ; Nataf, V ; Balogova, S ; Pontvert, D ; Lebret, T ; Guillonneau, B ; Cussenot, O ; Talbot, J-N</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pubmed_primary_285764233</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>fre</language><creationdate>2017</creationdate><topic>Adenocarcinoma - blood</topic><topic>Adenocarcinoma - diagnostic imaging</topic><topic>Adenocarcinoma - surgery</topic><topic>Aged</topic><topic>Biomarkers - blood</topic><topic>Choline - analogs & derivatives</topic><topic>Follow-Up Studies</topic><topic>Gallium Radioisotopes</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - blood supply</topic><topic>Neoplasm Recurrence, Local - diagnostic imaging</topic><topic>Neoplasm Recurrence, Local - surgery</topic><topic>Positron Emission Tomography Computed Tomography - methods</topic><topic>Prospective Studies</topic><topic>Prostate-Specific Antigen - blood</topic><topic>Prostatectomy</topic><topic>Prostatic Neoplasms - blood</topic><topic>Prostatic Neoplasms - diagnostic imaging</topic><topic>Prostatic Neoplasms - surgery</topic><topic>Radiopharmaceuticals</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gauthé, M</creatorcontrib><creatorcontrib>Belissant, O</creatorcontrib><creatorcontrib>Girard, A</creatorcontrib><creatorcontrib>Zhang Yin, J</creatorcontrib><creatorcontrib>Ohnona, J</creatorcontrib><creatorcontrib>Cottereau, A-S</creatorcontrib><creatorcontrib>Nataf, V</creatorcontrib><creatorcontrib>Balogova, S</creatorcontrib><creatorcontrib>Pontvert, D</creatorcontrib><creatorcontrib>Lebret, T</creatorcontrib><creatorcontrib>Guillonneau, B</creatorcontrib><creatorcontrib>Cussenot, O</creatorcontrib><creatorcontrib>Talbot, J-N</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Progrès en urologie (Paris)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gauthé, M</au><au>Belissant, O</au><au>Girard, A</au><au>Zhang Yin, J</au><au>Ohnona, J</au><au>Cottereau, A-S</au><au>Nataf, V</au><au>Balogova, S</au><au>Pontvert, D</au><au>Lebret, T</au><au>Guillonneau, B</au><au>Cussenot, O</au><au>Talbot, J-N</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>PET/CT and biochemical recurrence of prostate adenocarcinoma: Added value of 68 Ga-PSMA-11 when 18 F-fluorocholine is non-contributive</atitle><jtitle>Progrès en urologie (Paris)</jtitle><addtitle>Prog Urol</addtitle><date>2017-06</date><risdate>2017</risdate><volume>27</volume><issue>8-9</issue><spage>474</spage><pages>474-</pages><issn>1166-7087</issn><abstract>Since April 201, we have introduced PET/CT using a ligand of prostate-specific membrane antigen labeled with gallium-68 (PSMA-11). We aimed to evaluate its positivity rate and impact in patients presenting biochemical recurrence of prostate cancer whose
F-fluorocholine (FCH) PET/CT was non-contributive.
Patients were prospectively included between April and December 2016. PET/CT was performed 60min after injection of 2MBq/kg of body mass of
Ga-PSMA-11. Three anatomical areas were considered: prostatic lodge, pelvic lymph nodes and distant locations. The impact of PSMA-11 PET/CT was assessed by comparing changes in therapeutic strategy decided during multidisciplinary meeting.
Thirty-three patients were included. The mean PSA serum level measured on the month of the PSMA-11 PET/CT was 2,8ng/mL. Twenty-five (76%) PSMA-11 PET/CT were positive, 7 (21%) negative and 1 (3%) equivocal. Of 11 patients whose FCH PET/CT showed equivocal foci, PSMA-11 PET/CT confirmed those foci in 5 cases. Follow-up was available for 18 patients (55%). PSMA-11 PET/CT results led to a change in management in 12 patients (67%).
Ga-PSMA-11 PET/CT is useful in detecting recurrence of prostate cancer, by identifying residual disease which was not detected on other imaging modalities and by changing management of 2 patients out of 3.
5.</abstract><cop>France</cop><pmid>28576423</pmid><doi>10.1016/j.purol.2017.04.004</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1166-7087 |
| ispartof | Progrès en urologie (Paris), 2017-06, Vol.27 (8-9), p.474 |
| issn | 1166-7087 |
| language | fre |
| recordid | cdi_pubmed_primary_28576423 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adenocarcinoma - blood Adenocarcinoma - diagnostic imaging Adenocarcinoma - surgery Aged Biomarkers - blood Choline - analogs & derivatives Follow-Up Studies Gallium Radioisotopes Humans Male Middle Aged Neoplasm Recurrence, Local - blood supply Neoplasm Recurrence, Local - diagnostic imaging Neoplasm Recurrence, Local - surgery Positron Emission Tomography Computed Tomography - methods Prospective Studies Prostate-Specific Antigen - blood Prostatectomy Prostatic Neoplasms - blood Prostatic Neoplasms - diagnostic imaging Prostatic Neoplasms - surgery Radiopharmaceuticals Treatment Outcome |
| title | PET/CT and biochemical recurrence of prostate adenocarcinoma: Added value of 68 Ga-PSMA-11 when 18 F-fluorocholine is non-contributive |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T02%3A02%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=PET/CT%20and%20biochemical%20recurrence%20of%20prostate%20adenocarcinoma:%20Added%20value%20of%2068%20Ga-PSMA-11%20when%2018%20F-fluorocholine%20is%20non-contributive&rft.jtitle=Progre%CC%80s%20en%20urologie%20(Paris)&rft.au=Gauth%C3%A9,%20M&rft.date=2017-06&rft.volume=27&rft.issue=8-9&rft.spage=474&rft.pages=474-&rft.issn=1166-7087&rft_id=info:doi/10.1016/j.purol.2017.04.004&rft_dat=%3Cpubmed%3E28576423%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/28576423&rfr_iscdi=true |